Protocols
4 protocol(s) meet the specified criteria
Drug: REVLAMID
Protocol No.TitleStatus
54767414MMY2004Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell TransplantationOpen
CALGB50803A Phase II Trial of Lenalidomide (Revlimid™, CC-5013)(NSC #703813, IND #70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) Open (affiliates only)
DFCI10-106A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009).Open
LCCC1111An Open-Label Dose-Finding Study of Lenalidomide as Consolidation Followed by Lenalidomide Maintenance Therapy for Adults >/= 60 Years of Age with AML in Partial or Complete Response Following Conventional Induction TherapyOpen